Pharma Focus Asia
KP - Choose our fully recyclable blister films

Breakthrough CMG901 Drug Introduced for Advanced Gastric Cancer

Connoya introduced CMG901, novel drug for the treatment of Claudin 18.2-positive advanced gastric cancer. This new drug is indicated after first-line or treatment failure or intolerance.

CMG901 previously granted orphan drug designation and fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma. Hence, CMG901 serves as the better treatment of Claudin 18.2-positive advanced gastric cancer.

Gastric cancer is a malignant tumor of epithelial origin originating from stomach. Globally, more than 1 million new gastric cancer cases arise every year causing nearly 769,000 deaths.

During first diagnosis, due to the atypical early symptoms of gastric cancer, 80% to 90% of gastric cancer patients are in the advanced stage, losing the chance of radical surgery.

Since gastric cancer is highly heterogeneous, the targeted therapy drugs are scarce. Currently, there are no targeted drugs approved for first-line treatment of HER2 in market.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024